Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis

Nima Kokabi, Juan C. Camacho, Minzhi Xing, Deqiang Qiu, Hiroumi Kitajima, Pardeep Kumar Mittal, Hyun S. Kim

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).

Materials and methods: In a prospective study, 18 consecutive patients with unresectable infiltrative HCC and PVT underwent Y-90 therapy. MR imaging was obtained pre Y-90, and at 1 and 3 months post-therapy with DWI fat-suppressed tri-directional diffusion gradient (b = 50, 400, 800 s/mm2). Response was evaluated using target mRECIST and EASL. Relative change in apparent diffusion coefficient (ADC) value of tumors was evaluated. Statistical analysis using receiver operator characteristic curves was performed. Paired t test and Pearson correlation coefficient (r) were used to assess intra- and inter-observer variability. Survival analysis was performed using Kaplan-Meier estimation and log-rank test.

Results: Mean ADC values of all HCC’s at baseline and at 30-days post-Y90 therapy was 0.86 × 10−3 and 1.17×10−3 mm2/s, respectively (p < 0.001). Tumors with objective response by mRECIST had significantly increased ADC value when compared to “non-responders” (1.27 vs. 1.05×10−3 mm2/s, p = 0.002). A >30% increase in ADC value at 30-days was found to be at least 90% sensitive in predicting response at 90 days. A >30% increase in ADC value at 30-days predicted significantly prolonged survival.

Conclusion: A 30% increase in ADC value at 30-days measured post Y90 is a reproducible early imaging response biomarker predicting tumor response and prolonged survival following Y-90 therapy in infiltrative HCC with PVT.

Original languageEnglish (US)
Pages (from-to)969-978
Number of pages10
JournalAbdominal Imaging
Volume39
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Yttrium
Portal Vein
Hepatocellular Carcinoma
Thrombosis
Biomarkers
Survival
Therapeutics
Observer Variation
Survival Analysis
Tumor Biomarkers
Fats
Prospective Studies

Keywords

  • Diffusion weighted imaging
  • Early tumor response
  • Imaging biomarker
  • Infiltrative hepatocellular carcinoma
  • Portal vein thrombosis
  • Survival
  • Y-90

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. / Kokabi, Nima; Camacho, Juan C.; Xing, Minzhi; Qiu, Deqiang; Kitajima, Hiroumi; Mittal, Pardeep Kumar; Kim, Hyun S.

In: Abdominal Imaging, Vol. 39, No. 5, 01.01.2014, p. 969-978.

Research output: Contribution to journalArticle

@article{c26b116dd5d44adb8a3784b202c512c0,
title = "Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis",
abstract = "Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).Materials and methods: In a prospective study, 18 consecutive patients with unresectable infiltrative HCC and PVT underwent Y-90 therapy. MR imaging was obtained pre Y-90, and at 1 and 3 months post-therapy with DWI fat-suppressed tri-directional diffusion gradient (b = 50, 400, 800 s/mm2). Response was evaluated using target mRECIST and EASL. Relative change in apparent diffusion coefficient (ADC) value of tumors was evaluated. Statistical analysis using receiver operator characteristic curves was performed. Paired t test and Pearson correlation coefficient (r) were used to assess intra- and inter-observer variability. Survival analysis was performed using Kaplan-Meier estimation and log-rank test.Results: Mean ADC values of all HCC’s at baseline and at 30-days post-Y90 therapy was 0.86 × 10−3 and 1.17×10−3 mm2/s, respectively (p < 0.001). Tumors with objective response by mRECIST had significantly increased ADC value when compared to “non-responders” (1.27 vs. 1.05×10−3 mm2/s, p = 0.002). A >30{\%} increase in ADC value at 30-days was found to be at least 90{\%} sensitive in predicting response at 90 days. A >30{\%} increase in ADC value at 30-days predicted significantly prolonged survival.Conclusion: A 30{\%} increase in ADC value at 30-days measured post Y90 is a reproducible early imaging response biomarker predicting tumor response and prolonged survival following Y-90 therapy in infiltrative HCC with PVT.",
keywords = "Diffusion weighted imaging, Early tumor response, Imaging biomarker, Infiltrative hepatocellular carcinoma, Portal vein thrombosis, Survival, Y-90",
author = "Nima Kokabi and Camacho, {Juan C.} and Minzhi Xing and Deqiang Qiu and Hiroumi Kitajima and Mittal, {Pardeep Kumar} and Kim, {Hyun S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00261-014-0127-8",
language = "English (US)",
volume = "39",
pages = "969--978",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis

AU - Kokabi, Nima

AU - Camacho, Juan C.

AU - Xing, Minzhi

AU - Qiu, Deqiang

AU - Kitajima, Hiroumi

AU - Mittal, Pardeep Kumar

AU - Kim, Hyun S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).Materials and methods: In a prospective study, 18 consecutive patients with unresectable infiltrative HCC and PVT underwent Y-90 therapy. MR imaging was obtained pre Y-90, and at 1 and 3 months post-therapy with DWI fat-suppressed tri-directional diffusion gradient (b = 50, 400, 800 s/mm2). Response was evaluated using target mRECIST and EASL. Relative change in apparent diffusion coefficient (ADC) value of tumors was evaluated. Statistical analysis using receiver operator characteristic curves was performed. Paired t test and Pearson correlation coefficient (r) were used to assess intra- and inter-observer variability. Survival analysis was performed using Kaplan-Meier estimation and log-rank test.Results: Mean ADC values of all HCC’s at baseline and at 30-days post-Y90 therapy was 0.86 × 10−3 and 1.17×10−3 mm2/s, respectively (p < 0.001). Tumors with objective response by mRECIST had significantly increased ADC value when compared to “non-responders” (1.27 vs. 1.05×10−3 mm2/s, p = 0.002). A >30% increase in ADC value at 30-days was found to be at least 90% sensitive in predicting response at 90 days. A >30% increase in ADC value at 30-days predicted significantly prolonged survival.Conclusion: A 30% increase in ADC value at 30-days measured post Y90 is a reproducible early imaging response biomarker predicting tumor response and prolonged survival following Y-90 therapy in infiltrative HCC with PVT.

AB - Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).Materials and methods: In a prospective study, 18 consecutive patients with unresectable infiltrative HCC and PVT underwent Y-90 therapy. MR imaging was obtained pre Y-90, and at 1 and 3 months post-therapy with DWI fat-suppressed tri-directional diffusion gradient (b = 50, 400, 800 s/mm2). Response was evaluated using target mRECIST and EASL. Relative change in apparent diffusion coefficient (ADC) value of tumors was evaluated. Statistical analysis using receiver operator characteristic curves was performed. Paired t test and Pearson correlation coefficient (r) were used to assess intra- and inter-observer variability. Survival analysis was performed using Kaplan-Meier estimation and log-rank test.Results: Mean ADC values of all HCC’s at baseline and at 30-days post-Y90 therapy was 0.86 × 10−3 and 1.17×10−3 mm2/s, respectively (p < 0.001). Tumors with objective response by mRECIST had significantly increased ADC value when compared to “non-responders” (1.27 vs. 1.05×10−3 mm2/s, p = 0.002). A >30% increase in ADC value at 30-days was found to be at least 90% sensitive in predicting response at 90 days. A >30% increase in ADC value at 30-days predicted significantly prolonged survival.Conclusion: A 30% increase in ADC value at 30-days measured post Y90 is a reproducible early imaging response biomarker predicting tumor response and prolonged survival following Y-90 therapy in infiltrative HCC with PVT.

KW - Diffusion weighted imaging

KW - Early tumor response

KW - Imaging biomarker

KW - Infiltrative hepatocellular carcinoma

KW - Portal vein thrombosis

KW - Survival

KW - Y-90

UR - http://www.scopus.com/inward/record.url?scp=84930511531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930511531&partnerID=8YFLogxK

U2 - 10.1007/s00261-014-0127-8

DO - 10.1007/s00261-014-0127-8

M3 - Article

C2 - 24740759

AN - SCOPUS:84930511531

VL - 39

SP - 969

EP - 978

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

IS - 5

ER -